Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sep 15, 2015 Cytori Presentation with Scleroderma Twelve Month Follow Up Data Available for Investor Download
http://ir.cytori.com/investor-relations/default.aspx
Your welcome.....not in right now but watching closely
Titan Pharmaceuticals to Present at the BIO International Convention
MARKET WIRE 2:03 PM ET 6/10/2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 06/10/15 -- Titan Pharmaceuticals, Inc.(TTNP) , a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term drug delivery technology, announced today that President Sunil Bhonsle will present at the BIO International Convention 2015 being held June 16-18 at the Pennsylvania Convention Center in Philadelphia. The presentation will take place on Tuesday, June 16 at 4:15 p.m. in Theater 3.
Mr. Bhonsle will review topline results of the final Phase 3 trial of Probuphine® for the long-term maintenance treatment of opioid dependence. The trial met all primary and secondary efficacy endpoints and plans are under way for the resubmission of the New Drug Application (NDA) later this year. He will also provide an overview of the company's ProNeura for Parkinson's disease program and other upcoming milestones for 2015.
About the BIO International Convention
The BIO International Convention is considered one of the world's largest, most influential biotech meetings and regularly attracts 15,000 of the most powerful biotech and pharma players from 65 countries, offering powerful business partnering, networking and education that go far beyond professional development. For more information, please visit http://convention.bio.org.
About Titan Pharmaceuticals(TTNP)
Titan Pharmaceuticals Inc. (TTNP) , based in South San Francisco, CA, is a specialty pharmaceutical company developing proprietary therapeutics primarily for the treatment of serious medical disorders. The company's lead product candidate is Probuphine®, a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence. Probuphine employs Titan's proprietary drug delivery system ProNeura™, which is capable of delivering sustained, consistent levels of medication for six months or longer. Titan has granted North American commercial rights for Probuphine to Braeburn Pharmaceuticals. If approved, Probuphine would be the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. The ProNeura technology has the potential to be used in developing products for treating other chronic conditions, such as Parkinson's disease, where maintaining consistent blood levels of a dopamine agonist may benefit the patient and improve medical outcomes. For more information about Titan, please visit www.titanpharm.com.
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
CONTACT:
Titan Pharmaceuticals, Inc. (TTNP)
Sunil Bhonsle
President
(650) 244-4990
Investors:
Stephen Kilmer
(647) 872-4849
skilmer@titanpharm.com
Media:
Susan Thomas
(619) 540-9195
sthomas@titanpharm.com
8k out share offering not approved
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 21, 2015
Amedica Corporation
(Exact name of registrant as specified in its charter)
Delaware 001-33624 84-1375299
(State or other jurisdiction
of incorporation) (Commission
File Number) (IRS Employer
Identification No.)
1885 West 2100 South
Salt Lake City, UT 84,119
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (801) 839-3500
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
--------------------------------------------------------------------------------
Item 5.07 Submission of Matters to a Vote of Security Holders
The Annual Meeting of Stockholders (the “Annual Meeting”) of Amedica Corporation (the “Company”) was held on May 21, 2015. At the Annual Meeting, the stockholders voted on the following three proposals and cast their votes as described below.
Proposal No. 1: A proposal to approve an amendment to the Company’s 2012 Equity Incentive Plan increasing the number of shares authorized for awards under the plan by 1,000,000 to a total of 4,568,181 shares. This proposal was approved.
For Against Abstain Broker Non-vote
6,918,415 3,330,753 6,152 8,159,424
Proposal No. 2: A proposal to ratify the appointment of Mantyla McReynolds LLC as the Company's independent registered public accounting firm for the year ending December 31, 2015. This proposal was approved.
For Against Abstain Broker Non-vote
17,942,696 316,915 155,133 0
Proposal No. 3: A proposal to approve the issuance by the Company, in accordance with a Securities Purchase Agreement dated June 30, 2014, of common stock equal to 20% or more of the Company’s issued and outstanding shares of common stock on June 30, 2014, at a price that may be less than the greater of book or market value of the Company’s common stock; and. This proposal was not approved.
For Against Abstain Broker Non-vote
3,862,213 5,085,069 1,308,038 8,159,424
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AMEDICA CORPORATION
Date: May 21, 2015 /s/ Ty Lombardi
Ty Lombardi
Vice President, Finance and Principle Accounting Officer
Need that PR !
Ahoy matey.....when does the ship leave port? My gas tank is runnin low.......need some black gold...
It already did.....
no problem Tom........guess it's just a shell now?
I know it's been hard to watch alot of the run-ups taken down for small gains, but one of these times it will blow past .05 and never look back . Hang in there whocares ! I CARE !
Maybe this is why their so quiet...... here's an exerpt from the link from sticky note about their former CEO
www.linkedin.com/pub/phillip-greer/4/968/13
CEO Sciencelabs.com
Public Company; 11-50 employees; EKII; Education Management industry
2001 – April 2010 (9 years)
CEO of small public company that recently was restructured to manufacture and market science supplies to schools worldwide. We recently tok this firm private.
LOL.......hey bud
Keep whistling........Santa....lol....gonna buy some today and then just sit on some bids......looking good here!!!
Dewatering system is set in place before the new year ~ all go ! $
Nice movement !
Go PCFG !
News out today ~ Rexahn Awarded Patent in Japan for RX-0047
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it was awarded patent 4,546,454 entitled, “Antisense Oligonucleotides that Inhibit Expression of HIF-1,” by the Japanese Patent Office.
Corresponding patents have been issued to Rexahn in other jurisdictions, including the U.S. and Europe.
The Japan patent covers Rexahn’s preclinical compound RX-0047 and a method of inhibiting the expression of HIF-1 in human cells or tissues. HIF-1, a human protein, is involved in angiogenesis, cancer cell survival, radiation resistance and cancer metastasis. Increased HIF-1 levels are associated with poor prognosis and increased mortality in several tumors. RX-0047 has demonstrated the ability to inhibit the expression of HIF-1 and also to induce toxicity in several cancer cell lines. Preclinical studies to date have demonstrated potent anti-proliferative, anti-tumor and anti-metastatic activities.
Rick Soni, President of Rexahn, noted, “Obtaining this additional patent coverage for RX-0047 in the large pharmaceutical market of Japan is another step forward for the development of this compound, and helps strengthen our overall global intellectual property position.”
$1.00 sooner than you think !
VNDM now down to 1 order ~ .0002's coming today , if they decide to stay away and noone else moves up .
Today for me......
Lol.........they brought friends today....
Nice prices here........
Same here......been looking forward to Dec. for a while
Yes, excellent support here......and not a bad price to stock up
Lots of support at .05. December 23rd is when Iroquois death spiral financing will be finalized and paid in full. Glad this will be in the past. Let's hope for a strong 2011 .
lookie........lookie
yep..................well gone now
Thanks plugger.......I really didn't look at much throughout the day, put an early morning buy in for YMI and called it a day, had it at 1.96, it missed, so we'll see what tomorrow brings. This seems to be a pivitol area for this stock..., nice to flip at the moment..........
.....take care
.....bob
not really just noticed it myself
A recent enquirey.......by a friend.....
Sent: November-23-10 7:49 AM
To: info@nacelenergy.com
Cc:
Subject: Dear Gentlemen,
Gentlemen,
I've been a shareholder here for awhile now and was wondering how much dilution is left from the note holders ? No one wants to buy this stock anymore because it is getting continuously battered at the end of each day either by Insiders or your lender.
Shareholders have been trying to hit the ASK and bring this back to a respectable price but to no avail. We all know this can move fast on news, but the share price never stabilizes . I hope the dumping will be over soon and I give you my best on the Snowflake Project ~
**********************************************************************************
From: info@nacelenergy.com
To:
Sent: 11/24/2010 7:11:02 P.M. Central Standard Time
Subj: RE: Dear Gentlemen,
Hi Mr. ;
Thanks for your email. You are correct to notice the pressure on our stock due to the Note with Iroquois. We can advise you that the final instalment on this Note – i.e. payable in shares – was made effective November 23 – there may possibly be a true-up needed on December 23 – but essentially once these November 23 shares are liquidated by Iroquois, this Note will be paid in full. We will not enter into any similar future financings with Iroquois. Iroquois may or may not decide to exercise their warrants at some point – however, this will be additional capital to the Company.
We are diligently working on Snowflake, our Texas projects, and other opportunities – and look forward to an improved 2011.
Regards;
Murray Fleming
Director, Investor Relations
Nacel Energy Corporation
9375 E. Shea Blvd., Suite 100
Scottsdale, AZ 85260
Local (602) 235-0355
Toll Free/Fax (888) 242-5848
Human Genome shares fall on Benlysta concerns
By Associated Press
November 17, 2010
Shares of Human Genome Sciences Inc. fell Wednesday after a Food and Drug Administration advisory panel recommended approving the company's lupus drug, but raised concerns about the treatments overall effectiveness.
The drug's effectiveness on certain patient populations could play a factor in how large a revenue driver it becomes, if it reaches the market.
THE SPARK: On Tuesday, a FDA advisory panel voted 13 to 2 in favor of approving Benlysta, but experts on the panel stressed that more effective therapies were needed because the drug will not work for all patients and that the label should be restricted accordingly. The drug did not help African-Americans in the study and that population is three times more likely to have lupus than Caucasians. The vote on effectiveness for the drug was 10 to 5 in favor.
The FDA does not have to follow the advice of its advisory panels, but often does.
THE BIG PICTURE: If approved, Benlysta will be the first new drug to treat Lupus in over 50 years. It is designed to treat flare-ups and pain caused by condition, which is a little-understood and potentially fatal ailment in which the body attacks its own tissue and organs. The disease causes skin rashes, joint pain and inflammation of the kidneys and the fibrous tissue surrounding the heart.
The FDA is scheduled to make a decision on Benlysta by Dec. 9, and company executives suggested the drug could be available in the first quarter 2011.
THE ANALYSIS: Citi analyst Dr. Yaron Werber said the label for the drug will likely have "noticeable restrictions" if approved, and he cut his 2015 sales estimate to $1.6 billion from $2.6 billion.
Werber said up to 50 percent of lupus patients could be restricted from using the drug by the label in the U.S., and 25 percent in Europe, because it will likely exclude African-Americans and patients with kidney disease.
"We did not expect that the panel will be so vocal on the need for this restriction," Werber said, in a note to investors.
SHARE ACTION: Down $1.37, or 5.3 percent, to $24.51 in trading Wednesday. The stock has traded between $20.56 and $34.49 over the last 52 weeks.
Hi closenow........started with HGSI in January of '09, once we got into the mid 20's action on the board really wained. Hope your doing well with this stock it sure has been a beauty.......
I see also what I think is portfolio movement...... Started with this in August and I've been pleased with it's progress, recently been bying a little more and adding on some flips.
All after market.......tomorrow should be interesting......23.00/24.00 range was too tempting for me
November 16, 2010 5:39 PM ET
Human Genome Sciences and GlaxoSmithKline announce vote of FDA advisory committee to recommend approval of BENLYSTA for systemic Lupus Erythematosus Human Genome Sciences (HGSI) and GlaxoSmithKline PLC (GSK) announced that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted 13 to 2 to recommend that the FDA approve BENLYSTA (belimumab) for the treatment of autoantibody-positive patients with active systemic lupus erythematosus (SLE). The FDA Arthritis Advisory Committee is convened to provide the FDA with independent expert advice on a broad range of issues related to rheumatology drug products.
Wow they sure did..... hope they keep pouncing...lol. Trading seemed out of the recent norm, yesterdays close at 2.04 then aftermarket activity to 2.11, late news, annual report had nothing in to be concerned about......all in all.....I think we're in good shape here.
Added some there today.........NCEN running today
Just got some 77's Where ya been all day?